Conformal radiotherapy of clinically localized prostate cancer: analysis of rectal and urinary toxicity and correlation with dose-volume parameters

Tumori

Volumn 95, Issue 2, 2009, Pages 160-168

  Ballar, Andrea ^a   Salvo, Maurizio Di ^a   Lo, Gianfranco ^b   Ferrari, Gianmarco ^a   BeIdi, Debora ^a   Krengli, Marco ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b University Hospital Maggiore della Carita   (Italy)

Author keywords

Prostate cancer radio therapy; Toxicity

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLADDER CAPACITY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC TOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE SEVERITY; HISTOGRAM; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; ORGAN SIZE; PATIENT POSITIONING; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION INJURY; RECTUM; RECTUM HEMORRHAGE; RECTUM INJURY; RISK ASSESSMENT; URINARY TRACT INJURY;

EID: 67649130989     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500206     Document Type: Article

References (57)

1. Quaglia A, Parody S, Grosclaude Martinez-Garcia C, Coebergh 1W, Vercelli M: Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur I Cancer, 39: 654-665, 2003.
2. Pollack A, Zagars GK, Starkschall G, Antolak IA, Lee 11, Huang E, von Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Intl Radiat Oncol Biol Phys, 53: 1097-1105, 2002.
3. Magrini SM, Bertoni F, Vavassori V. Villa S, Cagna F, Maranzano F, Pertici M, Pradella R, Spediacci M A, Chiavacci A, Ambrosi E, Livi L, Magli A, Bellavita R, Bossi A, Biti G: Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998), Intl Radiat Oncol Biol Phys, 52: 1310-19, 2002.
4. Hanks GE, HanlonAL, SchultheisslE, PinoverwH, Mosas B, Epstein BE, Hunt MA: Dose escalation with 3D conformal treatment: five years outcome, treatment optimization, and future directions. Intl Radial Oncol Biol Phvs, 41:501-510, 1998.
5. Zietman AL, Coen II, Dallow KG, Shipley WU: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Intl Radiat Oncol Biol Phys, 32: 287-292, 1995.
6. Morris D, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM, Tepper JE: Evidence-based reviess of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiatixe. Intl Radiat Oncol Biol Phys, 62: 3-19, 2005.
7. Ranks GE, Hanlon AL, Pinover WH, Horwitz EM, Price PA, Schuitheiss T: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int I Radiat Oncol Biol Phys, 46: 823-832, 2000.
8. Zelefsky Ml, Fuks Z, Runt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. mt I Radiat Oncol Biol Phys, 53: 1111-1116, 2002,
9. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox ID, Perez CA, Sause 'WT, Doggett SB: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. mt J Radiat Oncol Biol Phys, 21: 935-939, 1991.
10. Letourneau D, WongJW, Oldham M, Gularn M, Watt L, Jaffray DA, Siewerdsen JR, Martinez AA: Cone-beam CT-guided radiation therapy: technical implementation. Radiother Oncol, 75: 279-286, 2005.
11. Peignaux K, Truc G, Barillot I, Ammor A, Naudv S. Créhange G, Maingon P: Clinical assessment of the use of the Sonarray system for daily prostate localization. Radiother Oncol, 81:176-178, 2006.
12. Speight IL, Roach III M: Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. I Clin Oncol, 25: 987-995, 2007.
13. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V,Valdagni R: Rectal dose-volume constraints in high-dose conformal radiotherapy for localized prostate cancer. mt I Radiat Oncol Biol Phys, 57: 953-962, 2003.
14. Greco C, Mazzetta C, Cattani F, Tosi G, Castiglioni 5, Fodor A, Orecchia R: Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate canceL Radiother Oncol, 69: 215-222, 2003.
15. Liu M, Pickles T, Berthelet E, Agranovich A, KwanW, Tyldesley 5, McKenzie M, Keyes M, Morris I, Pai H: Prostate cohort initiative, urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol, 74: 197-201, 2005.
16. Geinitz H, Zimmermann FB, Thamm R, Erber C, Muller T, Keller M, Busch R, Molls M: Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol, 79: 341-347, 2006.
17. Marzi S, Arcangeli G, Saracino B, Petrongari MG, Bruzzani ii V, laccarino G, Landoni V, Soriani A, Benassi M: Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Intl Radiat Oncol Biol Phys, 68: 41-49, 2007.
18. VavassoriV, Fiorino C, RancatiT, MagliA, Fellin G, Baccolmi M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P Valdagni R: Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. mt I Radiat Oncol Biol Phys, 67: 1401-1410, 2007.
19. Sobin H, Witteking C: TNM Classification of Malignant Tumors. UICC, 6th edn, Wiley-Liss, New York, 2002.
20. National Comprehensive Cancer Network (NCCN) prostate cancer. In: National Comprehensive Canccr Network Clinical Practice Guidelines in Oncology, version 1.2007. Jenkinstown, PA, National Comprehensive Cancer Network, March 2007.
21. International Commission of Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU, 1993.
22. International Commission on Radiation Units and Measurements. ICRU Report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999.
23. Cox JD, Stetz I, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 134 1-1346, 1995.
24. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys, 37: 1035-1041, 1997.
25. Roach M III, Hanks G, Thames H, Schellhammer P Shipley W, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Intl Radiat Oncol Biol Phys, 65: 965-974, 2006.
26. Dirix fl Haustermans K, Junius S, Withers R, Oyen R, Van Poppel H: The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol, 79: 1-14, 2006.
27. Bagshaw MA: Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement. Urol Clin North Am, 11: 297-304, 1984.
28. Asbell SO, Krall JM, Pipelich MV Baerwald H, Sause WT, Hanks GE, Perez CA: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Intl Radiat Oncol Biol Phys, 15: 1307- 1316, 1988.
29. Asbell SO, Martz KL, Pilepich MV Baerwald H, Sause WT, Doggett RL, Perez CA: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bNOMO (A2) and T2NOMO (B) prostate. IntJ Radiat Oncol Biol Phys, 17: 945-95 1, 1989.
30. Pilepich MV, Krall JM, Johnson RJ, SauseWt Perez CA, Zinninger M, Martz K: Extended field (periaortic) irradiation in carcinoma of the prostate-analysis of RTOG 75-06. Tnt 1 Radiat Oncol Biol Phys, 12: 345-351, 1986.
31. Roach MIII, DeSilvio M, Lawton C, UhlV, MachtayM, Seider MI, Rotman M, Jones C, Asbell SO, Valicenti RK, Han 5, Thomas CR Jr, Shipley WS: A phase III trial comparing whole pelvic versus prostate only radiotherapy and neoadjuvant concurrent versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group (RTOG) 9413.1 Clin Oncol, 21: 1904-1911, 2003.
32. Roach M III, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, ShipleyWU: Whole-pelvis, "minipelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Intl Radiat Oncol Biol Phys, 66: 647-653, 2006.
33. Lawton CA, Desilvio M, Roach M III, Uh1V, Kirsch R, Seider M, Rotman M, Jones C, Asbell 5, Valicenti R, Hahn 5, Thomas CR Jr: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjovant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Intl Radiat Oncol Biol Phys, 69: 646-655, 2007.
34. Storey MR, PollackA, Zagars G, Smith L, AntolalcJ, Rosen I: Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Intl Radiat Oncol Biol Phys, 48: 635-642, 2000.
35. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW: Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys, 62: 1297- 1308, 2005.
36. Peeters ST, Lebesque IV, Heemsbergen WD, van Putten WL, Slot A, Dielwart ME, Koper PC: Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate canceL Intl Radiat Oncol Biol Phys, 64: 1151-1161, 2006.
37. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. mt I Radiat Oncol Biol Phys, 68: 1424- 1430, 2007.
38. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. mt I Radiat Oncol Biol Phys, 70: 67-74, 2008.
39. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada R Magnani T, Fiorino C, Nahum A: Is the alpha-beta ratio of prostate cancer really low? A prospective non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiat Oncol, 75: 74- 82, 2005.
40. Skala M, Rosewall T, Dawson L, Divanbeigi L, Lockwood G, Thomas C, Crook I, Chung P Warde P Catton C: Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 68: 690-698, 2007.
41. Dale W, Campbell T, Ignacio L, Song E Kopnick M, Mamo C, Ray P, Vijayakumar 5: Self-assessed health related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient assessed bother or symptoms. Urology, 53: 359-366, 1999.
42. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate canceL Int J Radiat Oncol Biol Phys, 70: 67-74, 2008.
43. Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AiR Munoz F, Stasi M, Franzone P Vavassori V: Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. mt J Radiat Oncol Biol Phys, 71: 1065- 1073, 2008.
44. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart ME Bonfrer JM, Incrocci L, Lebesque IV: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol, 24: 1990- 1996, 2006.
45. Fiorino C, Cozzarini C, Vavassori V Sanguineti G, Bianchi C, Cattaneo GM, Foppiano F, Magli A, Piazzolla A: Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol, 64: 1-12, 2002.
46. Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque IV, Levendag PC: Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol, 73: 1-9, 2004.
47. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G, Valdagni R, Gabriele P: Emptyng the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol, 80: 363-370, 2006.
48. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, Gustafson G, Vicini F, Martinez A, Kestin LL: Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Intl Radiat Oncol BiolPhys, 69: 1100-1109, 2007.
49. Nakamura BA, Monti CR, Castilho LN, Trevisan FA, Valim AC, 48. Reinato IA: Prognostic factors for late urinary toxicity grade 2-3 after conformal radiation therapy on patients with prostate cancer. Int BrazJ Urol, 33: 652-661, 2007.
50. Dearnaley UP, Sydes MR, Langley RE, Graham JD, Huddart BA, Syndikus I, Matthews JH, Scrase CD, Jose CC, Logue I, Stephens RI, RTO 1 Collaborators: The early toxicity of esca lated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RTO1 trial (1SRCTN47772397). Radiother Oncol, 83: 31-41, 2007.
51. MoiseenkoV, Liu M, Kristensen S, Gelowitz G, Berthelet E: Effect of bladder filling on doses to prostate and organs at risk: a treatment planning study. I Appi Clin Med Phys, 12: 55-68, 2006.
52. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks, Poliack A: What dose of external-beam radiation is high enough for prostate cancer? mt J Radiat Oncol Biol Phys, 68: 682-689, 2007.
53. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P MartinezA, Michaiski J, PisanskyT, Sandier H, ShipleyW, Zelefsky M, Zietman A: Faiiure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? tnt J Radiat Oncol Biol Phys, (ii: 409-414, 2005.
54. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Della Croce A, Kantoff PW: 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA, 292: 821-827, 2004.
55. Bruns F, Franzki C,Wegener G, Karstens JH: Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. Anticancer Res, 27: 1847-1851, 2007.
56. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P MartinezA, Michalski I, PisanskyT, Sandier H, ShipleyW, Zelefsky M, Zietman A: Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int I Radiat Oncol Biol Phys, 57: 929-943, 2003.
57. Vicini FA, Kestin LL, Martinez AA: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553-561, 1999.